We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.
PRTK

Delisted

PRTK was delisted on the 20th of September, 2023.

Back to rankings

110 hedge funds and large institutions have $255M invested in Paratek Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 46 increasing their positions, 30 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

4% less funds holding

Funds holding: 114 → 110 (-4)

20% less call options, than puts

Call options by funds: $2.31M | Put options by funds: $2.9M

21% less capital invested

Capital invested by funds: $324M → $255M (-$68.3M)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

Holders
110
Holders Change
-4
Holders Change %
-3.51%
% of All Funds
2.52%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
12
Increased
46
Reduced
30
Closed
16
Calls
$2.31M
Puts
$2.9M
Net Calls
-$585K
Net Calls Change
+$153K

Top Buyers

Rank Fund Capital Flow
1
HCMT
Highland Capital Management (Texas)
Texas
+$10.8M
2
APCM
Arbiter Partners Capital Management
New York
+$7.73M
3
BlackRock
BlackRock
New York
+$6.28M
4
AC
Armistice Capital
New York
+$6.25M
5
GIM
Granahan Investment Management
Massachusetts
+$2M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$10.7M
3
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
-$6.48M
4
BC
Broadfin Capital
New York
-$6.21M
5
OP
Omni Partners
United Kingdom
-$2.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$2.86M +$1.46M +129,212 +86%
RAM
27
Roumell Asset Management
Maryland
$2.63M +$681K +60,183 +30%
GIM
28
Granahan Investment Management
Massachusetts
$1.8M +$2M +176,538 New
Goldman Sachs
29
Goldman Sachs
New York
$1.68M +$1.28M +113,505 +224%
PM
30
Prosight Management
Texas
$1.48M -$44.5K -3,930 -3%
Charles Schwab
31
Charles Schwab
California
$1.43M +$129K +11,384 +9%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.32M +$136K +11,980 +10%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$1.23M – – –
Morgan Stanley
34
Morgan Stanley
New York
$1.18M -$1.02M -90,315 -44%
Millennium Management
35
Millennium Management
New York
$1.18M +$373K +32,984 +40%
Boston Partners
36
Boston Partners
Massachusetts
$1.18M -$208K -18,400 -14%
IBT
37
International Biotechnology Trust
United Kingdom
$1.05M – – –
TMC
38
Trellus Management Company
Florida
$1.02M +$117K +10,300 +11%
RJA
39
Raymond James & Associates
Florida
$903K +$894 +79 +0.1%
SSA
40
Schonfeld Strategic Advisors
New York
$868K +$114K +10,100 +13%
Baird Financial Group
41
Baird Financial Group
Wisconsin
$809K +$898K +79,331 New
CCM
42
Cadence Capital Management
Massachusetts
$799K +$96.3K +8,509 +12%
TA
43
Teachers Advisors
New York
$784K +$371K +32,760 +74%
SAM
44
Stansberry Asset Management
Texas
$753K -$17.3K -1,531 -2%
VEA
45
Virtus ETF Advisers
New York
$752K +$351K +31,037 +73%
Allianz Asset Management
46
Allianz Asset Management
Germany
$688K +$46.3K +4,093 +6%
TCIM
47
TIAA CREF Investment Management
New York
$658K -$831K -73,471 -53%
Los Angeles Capital Management
48
Los Angeles Capital Management
California
$627K +$696K +61,486 New
QOP
49
Quinn Opportunity Partners
Virginia
$586K – – –
CS
50
Candriam SCA
Luxembourg
$581K – – –
1
2
3 4 5

PRTK Hedge Fund Activity: Q2 2018 in Review

110 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2018, worth a combined $255M — down 21% from $324M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PRTK and 12 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 46 added.

The largest buyer was Highland Capital Management (Texas), adding an estimated $10.8M. The largest seller was Fidelity Investments, exiting entirely with an estimated $16.2M sold.

  • 110 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2018, down from 114 in Q1 2018.
  • Funds reported $255M of Paratek Pharmaceuticals, Inc. stock for Q2 2018, down 21% quarter-over-quarter.
  • 12 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2018 and 16 closed out, a net change of -4 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2018 was Highland Capital Management (Texas), an estimated $10.8M added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q2 2018 was Fidelity Investments, an estimated $16.2M sold.

Based on aggregated 13F filings for Q2 2018.